Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

The promises and pitfalls of epigenetic therapies in solid tumours

(2009) Janet S. Graham et al.   EUROPEAN JOURNAL OF CANCER

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

(2009) Daniela E. Matei et al.   GYNECOLOGIC ONCOLOGY

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Ovarian cancer

(2009) Bryan T Hennessy et al.   LANCET

DNA hypomethylation in cancer cells

(2009) Melanie Ehrlich   Epigenomics

Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis

(2008) Yanfang Li et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage

(2008) George S Watts et al.   BMC Medical Genomics

Pharmaceutical Management of Ovarian Cancer

(2008) Maurie Markman   DRUGS

DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma

(2008) Qinghua Feng et al.   GYNECOLOGIC ONCOLOGY

DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment

(2008) Caroline A. Barton et al.   GYNECOLOGIC ONCOLOGY

Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma

(2008) Anatoliy Melnikov et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

(2007) Pedro T. Ramirez et al.   GYNECOLOGIC ONCOLOGY